3-氯噻吩-2-甲酰氯 | 86427-02-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 3-氯噻吩-2-甲酰氯
• 中文别名: 3-氯噻吩-2-羰酰氯
• 英文名称: 3-chlorothiophene-2-carbonyl chloride
• CAS: 86427-02-3
• 化学式: C₅H₂Cl₂OS
• 分子量: 181.042
• InChiKey: GCPHKTQMABHWPY-UHFFFAOYSA-N

物化性质

• 熔点：
  43-44
• 沸点：
  113°C 0,5mm
• 密度：
  1.543±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2934999090
• 危险品运输编号：
  UN 3261
• 储存条件：
  2-8°C

SDS

Name:	3-Chlorothiophene-2-carbonyl chloride 97% Material Safety Data Sheet
Synonym:
CAS:	86427-02-3

Section 1 - Chemical Product MSDS Name:3-Chlorothiophene-2-carbonyl chloride 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
86427-02-3	3-Chlorothiophene-2-carbonyl chloride	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 86427-02-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 113 deg C @0.5mmHg
Freezing/Melting Point: 43 - 44 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H2Cl2OS
Molecular Weight: 181

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 86427-02-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Chlorothiophene-2-carbonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 86427-02-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 86427-02-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 86427-02-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氯噻吩-2-甲酰氯 在 sodium hydrogen selenide 作用下， 以 乙醇 为溶剂， 反应 0.33h， 生成
  参考文献：
  名称：

  Novel Methylselenoesters as Antiproliferative Agents

  摘要：

  硒（Se）化合物在癌症治疗中具有潜在的治疗作用。重要的是，硒化合物的生物效应是通过其代谢产物发挥的，其中甲基硒醇（CH3SeH）是一个关键的执行者。在本研究中，我们开发了一系列具有不同骨架的甲基硒酯，旨在调节CH3SeH的释放。这十五种化合物遵循Lipinski的五规则，并且除了化合物1和14外，其药物相似性值均优于阳性对照甲基硒酸。对这些化合物进行了自由基清除活性评估，其中化合物11能减少DPPH和ABTS自由基。在五种癌细胞系（前列腺、结肠和肺癌，乳腺腺癌和慢性髓性白血病）和两种非恶性细胞系（肺和乳腺上皮）中评估了这些化合物的细胞毒性。十种化合物在72小时内在四种癌细胞系中GI50值低于10 μM。由于与甲基硒酸的相似性，化合物5和15被选为进一步在乳腺腺癌细胞系中进行作用机制表征。这两种化合物均诱导G2/M期阻滞，而细胞死亡部分通过caspase介导。还研究了它们的还原和代谢，这两种化合物都被证明是还原型酶硫氧还蛋白还原酶的底物。

  DOI：

  10.3390/molecules22081288
• 作为产物：
  描述：

  3-氨基-2-噻吩甲酸甲酯 在 sodium hydroxide 、 氯化亚砜 、 水 、 氢气 、 Nitrite 、 N,N-二甲基甲酰胺 作用下， 以 甲苯 为溶剂， 反应 3.0h， 生成 3-氯噻吩-2-甲酰氯
  参考文献：
  名称：

  Eller, Gernot A.; Haring, Andreas W.; Datterl, Barbara, Heterocycles, 2007, vol. 71, # 1, p. 87 - 104

  摘要：

  DOI：

文献信息

• Synthesis and antiproliferative activity of novel symmetrical alkylthio- and alkylseleno-imidocarbamates
  作者：Elena Ibáñez、Daniel Plano、María Font、Alfonso Calvo、Celia Prior、Juan Antonio Palop、Carmen Sanmartín

  DOI：10.1016/j.ejmech.2010.11.013

  日期：2011.1

  in the five cell lines tested. Therefore, compounds 2b and 8b were evaluated by flow cytometric analysis for their effects on cell cycle distribution and apoptosis in MCF-7 cells. 2b was the most active, with an apoptogenic effect similar to camptothecin, which was used as a positive control. Both of them provoked cell cycle arrest leading to the accumulation of cells in either G2/M and S phase. These

  这里描述的研究涉及一系列三十种新的对称取代的亚氨基硫代氨基甲酸酯和亚氨基硒代氨基甲酸酯衍生物的合成及其在体外对五种人类肿瘤细胞系的抗肿瘤活性的评估：乳腺腺癌（MCF-7），结肠癌（HT- 29），淋巴细胞白血病（K-562），肝癌（Hep-G2），前列腺癌（PC-3）和一种非恶性乳腺衍生细胞系（MCF-10A）。在至少一种细胞系中，十八种化合物的GI 50值低于10μM。事实证明，两种癌细胞（MCF-7和HT-29）对5种化合物（1b，2b，3b，4b和5b）最敏感），其生长抑制在纳摩尔范围内，化合物1b，3b，7b，8b和9b的值小于1μM。此外，所有上述化合物均显示出较低的GI 50比一些标准的化学治疗药物的参考值高。结果还表明，在硒位置的脂族链的性质（甲基比苄基更好）和杂原子的性质（Se比S更好）对化合物的抗增殖活性有显着影响。这些发现加强了我们先前关于硒甲基作为此类化合物生物活性支
• Carbodiimide coupling reagent
  申请人：Eli Lilly and Company

  公开号：US05998630A1

  公开（公告）日：1999-12-07

  The present invention relates to compounds used for increasing activation of the 5-HT1F receptor.

  本发明涉及用于增加5-HT1F受体激活的化合物。
• Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
  申请人：——

  公开号：US20030045546A1

  公开（公告）日：2003-03-06

  The present invention is directed to substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: 1 wherein Ar 1 , Ar 3 , A, B and D are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明涉及取代的3-芳基-5-芳基-[1,2,4]-噁二唑及其类似物，由以下式I表示： 1 其中Ar1，Ar3，A，B和D在此处定义。本发明还涉及发现具有式I的化合物是caspase的激活剂和凋亡诱导剂。因此，本发明的caspase激活剂和凋亡诱导剂可用于诱导在各种临床病况中发生未受控制的异常细胞生长和扩散的细胞死亡。
• [EN] PHOSPHATE/SULFATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN INTERACTING NIMA (PIN1)<br/>[FR] COMPOSES A BASE D'ESTERS DE SULFATE/PHOSPHATE ET COMPOSITIONS PHARMACEUTIQUES INHIBANT L'ACTIVITE DE NIMA INTERAGISSANT AVEC DES PROTEINES (PIN1)
  申请人：PFIZER

  公开号：WO2004087720A1

  公开（公告）日：2004-10-14

  Phosphate/sulfate ester compounds that modulate and/or inhibit the activity of protein interacting NIMA (PIN1), and to pharmaceutical compositions containing such compounds are described. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating disorders characterized by hypertension, inappropriate cell proliferation, infectious diseases, and neurodegenerative brain disorders, by administering effective amounts of such compounds.

  磷酸/硫酸酯化合物能够调节和/或抑制与蛋白质相互作用的NIMA（PIN1）的活性，以及包含此类化合物的药物组合物。本发明还涉及此类化合物和组合物的治疗或预防用途，以及通过施用有效量的此类化合物来治疗表现为高血压、不适当的细胞增殖、传染性疾病和神经退行性脑障碍的方法。
• Phosphate/sulfate ester compounds and pharmaceutical composition for inhibiting protein interacting NIMA (PIN1)
  申请人：Dagostino Eleanor

  公开号：US20050250742A1

  公开（公告）日：2005-11-10

  Phosphate/sulfate ester compounds that modulate and/or inhibit the activity of protein interacting NIMA (PIN1), and to pharmaceutical compositions containing such compounds are described. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating disorders characterized by hypertension, inappropriate cell proliferation, infectious diseases, and neurodegenerative brain disorders, by administering effective amounts of such compounds.

  磷酸/硫酸酯化合物能够调节和/或抑制与蛋白质相互作用的NIMA（PIN1）的活性，以及包含此类化合物的药物组合物。本发明还涉及此类化合物和组合物的治疗或预防用途，以及通过施用有效量的此类化合物来治疗表现为高血压、不适当的细胞增殖、感染性疾病和神经退行性脑障碍的方法。